Priyanka Arora

Priyanka Arora

Auto-generated profile, based on publicly available information

Priyanka Arora

Gilead Sciences, Inc. Foster City CA USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2024 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
KMKaram Mounzer
Karam Mounzer
JSJihad Slim
Jihad Slim
MRMoti Ramgopal
Moti Ramgopal
MHMalcolm Hedgcock
Malcolm Hedgcock
MBMark Bloch
Mark Bloch
SSSorana Segal-Maurer
Sorana Segal-Maurer
Background: Complex antiretroviral therapy (ART) regimens, such as those requiring multiple tablets, several doses per day, or both, can negatively affect quality of life and treatment adherence among people with human immunodeficiency virus (HIV). Methods: ARTISTRY-1 is a phase 2/3, operationally seamless, randomized, open-label, multicenter, active-controlled study (GS-US-621-6289; NCT05502341). Phase 2 of the study enrolled adults with plasma HIV-1 RNA <50 copies/mL receiving a complex ART regimen for ≥6 months. Efficacy and safety outcomes were evaluated after a switch to bictegravir (BIC) (75-mg) + lenacapavir (LEN) (25- or 50-mg) regimens, compared with continuing on a complex ART regimen through 24 weeks. Results: Overall, 128 participants were assigned randomly to begin BIC 75 mg + LEN 25 mg (n = 51) or BIC 75 mg + LEN 50 mg (n = 52) or continue on their complex ART regimen (n = 25). At week 24, HIV-1 RNA was ≥50 copies/mL in 0 of 51, 1 of 52 (1.9%), and 0 of 25 participants in the 3 groups, respectively. CD4 cell counts and percentages remained stable through week 24; the median change from baseline in CD4 cell count (interquartile range) was 18 (−39 to 70), −16 (−80 to 93), and 42 (−36 to 90) cells/µL, respectively. There were no study discontinuations due to a serious adverse event through week 24. Both BIC + LEN dosing regimens were well tolerated, with similar safety profiles observed between groups. Conclusions: These data support the continued evaluation of the combination of BIC and LEN to optimize treatment in people with HIV and virologic suppression who are receiving complex ART regimens.

3 April 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
PDPankaj Desai
Pankaj Desai
AKAniruddha Sunil Karve
Aniruddha Sunil Karve
MZMisam Zawit
Misam Zawit
PAPriyanka Arora
Priyanka Arora
NDNimita Dave
Nimita Dave
TWTrisha Wise-Draper
Trisha Wise-Draper
Purpose: High-grade gliomas (HGG) carry a poor prognosis, with glioblastoma accounting for almost 50% of primary brain malignancies in the elderly. Unfortunately, despite the use of multiple treatment modalities, the prognosis remains poor in this population. Our preclinical studies suggest that the presence of aromatase expression, encoded by CYP19A1, is significantly upregulated in HGGs. Remarkably, we find that letrozole (LTZ), an FDA-approved aromatase inhibitor, has marked activity against HGGs. Patients and Methods: We conducted a phase 0/I single-center clinical trial (NCT03122197) to assess the tumoral availability, pharmacokinetics (PK), safety, and tolerability of LTZ in recurrent patients with HGG. Planned dose cohorts included 2.5, 5, 10, 12.5, 15, 17.5, and 20 mg of LTZ administered daily pre- and postsurgery or biopsy. Tumor samples were assayed for LTZ content and relevant biomarkers. The recommended phase 2 dose (R2PD) was determined as the dose that resulted in predicted steady-state tumoral extracellular fluid (ECF; Css,ecf) >2 μmol/L and did not result in ≥33% dose-limiting adverse events (AE) assessed using CTCAE v5.0. Results: Twenty-one patients were enrolled. Common LTZ-related AEs included fatigue, nausea, musculoskeletal, anxiety, and dysphoric mood. No DLTs were observed. The 15 mg dose achieved a Css,ecf of 3.6 ± 0.59 μmol/L. LTZ caused dose-dependent inhibition of estradiol synthesis and modulated DNA damage pathways in tumor tissues as evident using RNA-sequencing analysis. Conclusions: On the basis of safety, brain tumoral PK, and mechanistic data, 15 mg daily is identified as the RP2D for future trials.

17 June 2024 in Cancer Research
Verified
Journal Article
Closed access
PDF file
NONicole Oatman
Nicole Oatman
MGMruniya V. Gawali
Mruniya V. Gawali
SCSunny Congrove
Sunny Congrove
RCRomán Cáceres
Román Cáceres
ASAbitha Sukumaran
Abitha Sukumaran
Biplab DasguptaBiplab Dasgupta
Biplab Dasgupta
The genetic landscape of cancer cells can lead to specific metabolic dependencies for tumor growth. Dietary interventions represent an attractive strategy to restrict the availability of key nutrients to tumors. In this study, we identified that growth of a subset of melanoma was severely restricted by a rationally designed combination therapy of a stearoyl-CoA desaturase (SCD) inhibitor with an isocaloric low-oleic acid diet. Despite its importance in oncogenesis, SCD underwent monoallelic codeletion along with PTEN on chromosome 10q in approximately 47.5% of melanoma, and the other SCD allele was methylated, resulting in very low-SCD expression. Although this SCD-deficient subset was refractory to SCD inhibitors, the subset of PTEN wild-type melanoma that retained SCD was sensitive. As dietary oleic acid could potentially blunt the effect of SCD inhibitors, a low oleic acid custom diet was combined with an SCD inhibitor. The combination reduced monounsaturated fatty acids and increased saturated fatty acids, inducing robust apoptosis and growth suppression and inhibiting lung metastasis with minimal toxicity in preclinical mouse models of PTEN wild-type melanoma. When combined with anti-PD1 immunotherapy, the SCD inhibitor improved T-cell functionality and further constrained melanoma growth in mice. Collectively, these results suggest that optimizing SCD inhibitors with diets low in oleic acid may offer a viable and efficacious therapeutic approach for improving melanoma treatment. Significance: Blockade of endogenous production of fatty acids essential for melanoma combined with restriction of dietary intake blocks tumor growth and enhances response to immunotherapy, providing a rational drug–diet treatment regimen for melanoma.

15 June 2025 in The Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PAPriyanka Arora
Priyanka Arora
HLHui Liu
Hui Liu
JLJohn Ling
John Ling
JHJason T. Hindman
Jason T. Hindman
DMDhananjay D. Marathe
Dhananjay D. Marathe
In addition to antiretroviral therapy (ART), people with HIV often take medications to treat comorbidities. It is therefore important to assess these medications for potential drug‐drug interactions, which may affect the safety and efficacy of ART. Three phase I studies were conducted in adult participants without HIV. The pharmacokinetics (PK) and safety of bictegravir (administered alone or as bictegravir/emtricitabine/tenofovir alafenamide fumarate [TAF]) were assessed when co‐administered with inducers (rifampin, rifabutin, and rifapentine) or inhibitors (atazanavir ± cobicistat, darunavir + cobicistat, and voriconazole) of cytochrome P450 3A4 (CYP3A4), uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), and/or P‐glycoprotein (P‐gp). PK parameters were compared using analysis of variance to calculate geometric least‐square mean ratios and 90% confidence intervals. Overall, 172 participants were enrolled. CYP3A4 inhibition (voriconazole) moderately increased bictegravir exposure (61% increase in area under the concentration‐time curve extrapolated to infinity [AUC inf ]), whereas dual CYP3A4 and UGT1A1 inhibition (atazanavir) led to a 315% increase in AUC inf . P‐gp inhibition had a minimal effect on bictegravir exposure. Induction of CYP3A4, UGT1A1, and/or P‐gp by rifampin, rifabutin, and rifapentine led to decreases in bictegravir exposure and/or trough concentration (C trough ). Bictegravir and bictegravir/emtricitabine/TAF were well tolerated alone and in combination with other drugs. Inhibition of CYP3A4 or UGT1A1 alone is unlikely to cause clinically meaningful changes in bictegravir exposure; only potent inhibitors of both pathways are expected to significantly affect bictegravir PK. Induction of CYP3A4 with/without UGT1A1 significantly influenced bictegravir PK, although C trough remained above the protein‐adjusted 95% effective concentration. These findings should be considered when co‐administering medications with bictegravir.

7 January 2026 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PAPriyanka Arora
Priyanka Arora
JHJason T. Hindman
Jason T. Hindman
SWSteve West
Steve West
JLJohn Ling
John Ling
RPRamesh Palaparthy
Ramesh Palaparthy
DMDhananjay D. Marathe
Dhananjay D. Marathe
The mechanism of action of integrase strand transfer inhibitors involves binding to magnesium ions in the active site of the HIV integrase enzyme, making them susceptible to chelation-type drug–drug interactions with metal cation–containing medications. This study evaluated the potential of metal cation–containing antacids and mineral supplements to impact bictegravir (BIC) exposure and assessed alternative approaches for combined use. This was an open-label, single-dose, Phase 1 study in adult participants without HIV. The pharmacokinetics and safety of BIC (administered as part of a single-tablet combination with emtricitabine [F] and tenofovir alafenamide [TAF; B/F/TAF]) were assessed when co-administered with maximum-strength aluminum/magnesium-containing antacid (referred to as “aluminum/magnesium-containing antacid”), calcium carbonate, or ferrous fumarate under fasted and fed conditions, and administered 2 hours before or after the antacid. Pharmacokinetic parameters were compared using analysis of variance to calculate geometric least-squares mean ratios and 90% confidence intervals. Forty-two participants were enrolled. BIC exposure (area under the plasma concentration–time curve extrapolated to infinity) was reduced by 79%, 33%, and 63%, respectively, when co-administered with aluminum/magnesium-containing antacid, calcium carbonate, and ferrous fumarate under fasted conditions. Co-administration of B/F/TAF with calcium carbonate or ferrous fumarate with a meal and administration of B/F/TAF 2 hours before the antacid reduced the impact of the interactions. B/F/TAF was well tolerated alone or in combination with metal cation–containing medications. Co-administration of BIC and calcium/iron-containing supplements with a meal and administration of BIC 2 hours or more before aluminum/magnesium-containing antacids are some of the effective strategies to mitigate chelation effects on BIC exposure. This study was registered at NCT05502341 / NCT06333808 .